PAI-1 – Published Papers Using Affinity Biologicals Products


TE Riehl, L He, L Zheng, S Greco… – … of Thrombosis and …, 2011 – Wiley Online Library
Biotechnology, Santa Cruz, CA, USA), mouse monoclonal anti-COX-2 (610204, 1:500; BD Biosciences, San Jose, CA, USA), rabbit anti-human PGI synthase (SC-20933, 1:200; Santa Cruz) and sheep anti-human PAI-1 (SAPAI-IG, 1:500; Affinity Biologicals, Ontario, Canada).

The antifibrinolytic function of factor XIII is exclusively expressed through

SR Fraser, NA Booth… – 2011
isothiocyanate (FITC) labeled fibrinogen was added to pooled normal plasma (PNP) or plasma depleted of FXIII, α2AP, TAFI or PAI (Affinity Biologicals Inc, Canada). or α2AP (Affinity Biologicals).


VG Nielsen – Blood Coagulation & Fibrinolysis, 2009 –
Blood Coagulation & Fibrinolysis: April 2009 – Volume 20 – Issue 3 – p 191 A second series of experiments with CTI utilized plasminogen activator inhibitor 1 (PAI-1) deficient plasma (<0.01 ng/ml; Affinity Biologicals Inc., Ancaster, Ontario, Canada) that had 0 or 25 μg/ml of potato ..

VG Nielsen, JK Kirklin… – Blood Coagulation & …, 2009 –
The following immunodepleted plasma types were obtained from Affinity
Biologicals, Inc., Ancaster, Ontario, Canada: plasminogen activator inhibitor type 1 (PAI-1)-deficient plasma (<0.5 ng/ml) with a PT of 14.3 s, an aPTT of 38.5 s, and a fibrinogen ..